# OrphanCure Full Pipeline Report: repodb_074e03e7fac6728e

- Drug: Irinotecan
- Disease: signet ring adenocarcinoma of the rectum
- Mode: no_graph_features
- Status: completed
- Final assessment: Unlikely

This generated report is for research support only and is not medical advice.

## Structured Output

```json
{
  "sections": {
    "1_executive_summary": {
      "conclusion": "Unlikely",
      "confidence": "Low",
      "summary": "There is no direct evidence to support or refute the repurposing of irinotecan for rectal signet ring cell adenocarcinoma. The available literature search yielded no relevant papers, indicating a significant lack of research in this specific area.",
      "evidence_counts": {
        "total_papers": 0,
        "supporting": 0,
        "contradicting": 0,
        "inconclusive": 0
      },
      "common_targets_count": 0
    },
    "2_normalized_hypothesis": {
      "statement": "Repurpose IRINOTECAN for rectal signet ring cell adenocarcinoma",
      "drug": {
        "id": "CHEMBL481",
        "name": "IRINOTECAN",
        "aliases": [
          "CPT-11",
          "Camptosar",
          "Irinotecan hydrochloride",
          "Onivyde",
          "Topoisomerase 1 inhibitor"
        ],
        "resolution_method": "auto"
      },
      "disease": {
        "id": "MONDO_0004336",
        "name": "rectal signet ring cell adenocarcinoma",
        "aliases": [
          "Rectal signet ring carcinoma",
          "Signet ring cell adenocarcinoma of the rectum",
          "Adenocarcinoma, signet ring cell type, rectum",
          "Rectal SRC",
          "Signet ring cell adenocarcinoma, rectal"
        ],
        "resolution_method": "auto"
      }
    },
    "3_mechanistic_rationale": {
      "total_mechanisms": 0,
      "mechanisms": []
    },
    "4_target_overlap_summary": {
      "total_overlapping": 0,
      "top_targets": []
    },
    "5_literature_evidence_summary": {
      "total_retrieved": 0,
      "polarity": {
        "supports": 0,
        "contradicts": 0,
        "inconclusive": 0
      },
      "support_ratio": "No papers retrieved",
      "queries_used": 10,
      "top_papers": []
    },
    "6_contradictory_evidence": {
      "count": 0,
      "claims": []
    },
    "7_confidence_assessment": {
      "overall": "Low",
      "dimensions": {
        "mechanistic_strength": "Low",
        "literature_strength": "Low",
        "clinical_evidence": "Low"
      },
      "quality_scorecard": {
        "overall_score": 0.388,
        "decision": "rerun",
        "dimensions": {
          "completeness": {
            "score": 0.8,
            "reason": "4/5 sections present"
          },
          "evidence_support": {
            "score": 0.0,
            "reason": "No claims generated"
          },
          "citation_validity": {
            "score": 0.0,
            "reason": "0 total citations"
          },
          "mechanistic_specificity": {
            "score": 0.0,
            "reason": "0/0 claims reference targets"
          },
          "contradiction_handling": {
            "score": 0.3,
            "reason": "No contradiction analysis"
          },
          "traceability": {
            "score": 0.0,
            "reason": "0/0 claims have provenance"
          },
          "output_structure": {
            "score": 1.0,
            "reason": "Executive summary + confidence assessment"
          },
          "actionability": {
            "score": 1.0,
            "reason": "3 next steps, 3 data gaps identified"
          }
        },
        "weak_dimensions": [
          "evidence_support",
          "citation_validity",
          "mechanistic_specificity",
          "contradiction_handling",
          "traceability"
        ],
        "rerun_targets": [
          "LiteratureAgent",
          "MechanismAgent",
          "SynthesisCriticAgent"
        ]
      }
    },
    "8_risk_flags_limitations": {
      "risk_flags": [
        "Lack of specific research may indicate poor preclinical or clinical outcomes."
      ],
      "limitations": [
        "The analysis is severely limited by the absence of any retrieved literature.",
        "No mechanistic data was provided to assess potential biological plausibility."
      ],
      "missing_data": [
        "Direct evidence of irinotecan efficacy in rectal signet ring cell adenocarcinoma.",
        "Preclinical studies evaluating irinotecan in relevant cell lines or animal models.",
        "Clinical trial data, even if retrospective, for this specific indication."
      ]
    },
    "9_recommended_next_steps": {
      "clinical_next_steps": [
        "Conduct a comprehensive literature search using broader terms related to irinotecan and signet ring cell adenocarcinoma of the gastrointestinal tract.",
        "Investigate preclinical studies or case reports that might indirectly link irinotecan to signet ring cell histology.",
        "Explore the known mechanisms of irinotecan and compare them to the molecular pathways implicated in rectal signet ring cell adenocarcinoma."
      ]
    },
    "10_claim_evidence_table": {
      "total_claims": 0,
      "claims": []
    },
    "11_provenance_appendix": {
      "total_entries": 0,
      "entries": []
    }
  },
  "metadata": {
    "run_id": "e8bb65bfe2b3",
    "created_at": "2026-06-03T12:28:09.059630+00:00",
    "drug": "IRINOTECAN",
    "disease": "rectal signet ring cell adenocarcinoma",
    "total_claims": 0,
    "quality_score": 0.3875,
    "reruns": 2
  }
}
```
